Comparison · NCT03932682-sae
QIVc vs Comparator: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. QIVc vs Comparator: serious adverse events. Trial comparisons, record NCT03932682-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03932682-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0224 | 0.0176 | 0.0285 | wilson | |
| Risk in group 2 | 0.0296 | 0.0239 | 0.0365 | wilson | |
| Risk difference, group 1 minus group 2 | -0.00716 | -0.0156 | 0.00114 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.758 | 0.55 | 1.04 | log | |
| Odds ratio, group 1 over group 2 | 0.752 | 0.541 | 1.05 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on QIVc than on Comparator | 140 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | QIVc | Cell-derived Quadrivalent Influenza Vaccine~QIVc: QIVc is a quadrivalent vaccine and contains 2 influenza type A strains and 2 influenza type B lineages recommended by World Health Organization (WHO) for inclusion in the quadrivalent vaccine formulation for the influenza season corresponding to the season of conduct of study. | 64 | 2,856 | EG000 |
| Group 2 | Comparator | Non-influenza Comparator~Comparator: Meningococcal Group C Polysaccharide Conjugate Vaccine (NeisVac-C) | 84 | 2,841 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
Unsolicited AEs: Day 1 through Study Completion, ie, Day 1 to Day 181/end of influenza season for previously vaccinated subjects and Day 1 to Day 209/end of influenza season for not previously vaccinated subjects Solicited AEs: 7 days following each vaccination in the treatment period, ie, Day 1 to Day 7 for previously vaccinated subjects and Day 1 to Day 7 and Day 29 to Day 35 for not previously vaccinated subjects
Source ClinicalTrials.gov
Trial
- Title
- Efficacy Study With QIVc in Pediatric Subjects
- NCT number
- NCT03932682
- Phases
- PHASE3
- Conditions
- Influenza, Human
- Interventions
- QIVc, Comparator
- Lead sponsor
- Seqirus
- Results first posted
- 2025-03-04
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT03932682?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT03932682-sae